Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial

This RCT (n=61) found that sputum eosinophil percentage decreased from 4.4% to 1.1% with fevipiprant compared to a reduction from 4.6% to 3.9% with placebo. No deaths or serious adverse events were reported.